Celltrion, Inc.
068270
Rang in Aktien
#720
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Aktienkurs
$146.63
Marktkapitalisierung
$33.44B
Veränderung (1 Tag)
-1.52%
Veränderung (1 Jahr)
23.60%
Land
KR
Handel Celltrion, Inc. (068270)
Kategorie
Healthcare
Anzahl der ausstehenden Aktien von Celltrion, Inc. (068270)
Anzahl der ausstehenden Aktien zum June 2026: 233.25M
Laut den neuesten Finanzberichten und dem Aktienkurs von Celltrion, Inc. beträgt die aktuelle Anzahl der ausstehenden Aktien 233.25M. Am Ende von December 2024 hatte das Unternehmen 217.00M ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von Celltrion, Inc. (068270) von 2007 bis 2026
Ausstehende Aktien am Ende jedes Jahres
| Jahr | Ausstehende Aktien | ändert |
|---|---|---|
| 2026 (TTM) | 233.25M | 0.99% |
| 2025 | 230.96M | 6.43% |
| 2024 | 217.00M | 52.04% |
| 2023 | 142.73M | 3.35% |
| 2022 | 138.10M | -4.67% |
| 2021 | 144.87M | 0.15% |
| 2020 | 144.65M | 0.14% |
| 2019 | 144.44M | -0.05% |
| 2018 | 144.52M | 0.11% |
| 2017 | 144.35M | 0.26% |
| 2016 | 143.98M | 2.91% |
| 2015 | 139.90M | 2.76% |
| 2014 | 136.14M | -0.01% |
| 2013 | 136.16M | -0.96% |
| 2012 | 137.49M | -0.65% |
| 2011 | 138.39M | 4.84% |
| 2010 | 132.00M | 8.34% |
| 2009 | 121.83M | 3.78% |
| 2008 | 117.40M | 1,578.29% |
| 2007 | 7.00M | 0.00% |
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
| Unternehmen | Ausstehende Aktien | Unterschied | Land |
|---|---|---|---|
| 253.90M | 8.86% |
US
|
|
| 396.00M | 69.78% |
US
|
|
| 478.91M | 105.33% |
AU
|
|
| 0.00 | -100.00% |
BE
|
|
| 62.19M | -73.34% |
NL
|
